LeMaitre Vascular’s (LMAT) “Outperform” Rating Reaffirmed at Barrington Research

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Barrington Research in a report released on Wednesday,Benzinga reports. They presently have a $120.00 target price on the medical instruments supplier’s stock. Barrington Research’s price target points to a potential upside of 29.21% from the stock’s previous close.

Several other research analysts also recently commented on the company. Citizens Jmp lifted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Weiss Ratings raised shares of LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 20th. Finally, Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Stock Performance

LMAT stock traded up $1.25 during trading hours on Wednesday, reaching $92.87. The stock had a trading volume of 30,424 shares, compared to its average volume of 224,043. The stock has a 50-day simple moving average of $106.84 and a 200 day simple moving average of $95.71. LeMaitre Vascular has a fifty-two week low of $79.00 and a fifty-two week high of $118.01. The stock has a market capitalization of $2.12 billion, a PE ratio of 34.27, a price-to-earnings-growth ratio of 2.54 and a beta of 0.54. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same period last year, the business posted $0.48 EPS. LeMaitre Vascular’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts predict that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. Glenmede Trust Co. NA raised its position in shares of LeMaitre Vascular by 14.8% in the 1st quarter. Glenmede Trust Co. NA now owns 9,547 shares of the medical instruments supplier’s stock valued at $1,042,000 after buying an additional 1,234 shares in the last quarter. Bank of America Corp DE raised its position in LeMaitre Vascular by 39.0% during the first quarter. Bank of America Corp DE now owns 180,095 shares of the medical instruments supplier’s stock valued at $19,661,000 after purchasing an additional 50,497 shares in the last quarter. Janus Henderson Group PLC lifted its stake in LeMaitre Vascular by 28.8% during the first quarter. Janus Henderson Group PLC now owns 10,832 shares of the medical instruments supplier’s stock worth $1,183,000 after purchasing an additional 2,422 shares during the last quarter. Smith Group Asset Management LLC boosted its holdings in shares of LeMaitre Vascular by 69.0% in the 1st quarter. Smith Group Asset Management LLC now owns 6,985 shares of the medical instruments supplier’s stock valued at $763,000 after purchasing an additional 2,851 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 28.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier’s stock valued at $152,000 after purchasing an additional 308 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.